No abstract

BACKGROUND AND OBJECTIVE High doses of flutamlde, which is the only antiandrogen that specifically blocks the androgen receptor, have recently been used with good clinical results in women wlth hirsutism. Since regression of hair growth requires long-term therapy, clinical and economic considerations are important. The use of the lowest efficacious dosage could reduce costs. This study was undertaken to compare safety and efficacy of a low dose of flutamide (125 mg twice daily) alone and in combination with a triphasic oral contraceptive (OC) in women with idiopathic hirsutism. PATIENTS Flutamide was administered orally in a low dose of 125mg twice daily for 12 months alone in women with no risk of pregnancy or during the use of an oral contraceptive. MEASUREMENTS Women were seen every 3 months and were evaluated for hirsutism score, hormone and llpld measurements. DESIGN The study, which was conducted as a prospective open trial, was proposed to patients with idiopathic hirsutism, that is, with serum androgen levels in normal range and LHlFSH ratio less than 2. RESULTS A statistically significant decrease in hirsutlsm score as compared to baseline was observed after only 3

SummaryBACKGROUND AND OBJECTIVE Recent data Indicate that oral medroxyprogesterone acetate (MPA) has Ilmlted unfavourable, neutral or even favourable effects on serum llpld fractlons when added to oestrogen replacement therapy. The purpose of this study was to evaluate the serum llpid fractions at the beglnnlng and at the end of each phase of a sequentially comblned resplacement cycle comparing the oral and the transdermal routes of oestrogen admlnistratlon. DESIGN Randomized study with a matched control group. Oral conjugated oestrogens (OCE, 0.625 mg) or transdermal oestradlol (TE 50pg) was taken from day 1 to day 25 and MPA (5mg) added on days 14 to 25. Serum lipids were evaluated on days 1, 14 and 25 of monthly replacement cycles.